Glass House Brands (GLAS) Depreciation & Amortization (CF) (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Depreciation & Amortization (CF) of $4.0 million for Q1 2026, up 4.82% year-over-year from $3.8 million in Q1 2025, and up 23.22% quarter-over-quarter from $3.3 million in Q4 2025.
Glass House Brands (GLAS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 4.82% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $15.2 million (changed 0.13% YoY), while the FY2025 annual figure was $15.0 million, changed 0.29% from the prior year.
- Depreciation & Amortization (CF) improved to $4.0 million in Q1 2026 per GLAS's latest filing, from $3.3 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $4.0 million in Q1 2026 and bottomed at $2.6 million in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $3.6 million across 5 years, with a median of $3.7 million in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 339.13% — and 2025, when it fell 15.75%.
- Glass House Brands' Depreciation & Amortization (CF) stood at $3.4 million in 2022, then advanced by 3.88% to $3.5 million in 2023, then advanced by 9.27% to $3.9 million in 2024, then fell by 15.75% to $3.3 million in 2025, then grew by 23.22% to $4.0 million in 2026.
- Business Quant data shows GLAS's Depreciation & Amortization (CF) at $4.0 million in Q1 2026, $3.3 million in Q4 2025, and $4.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | 3.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.02 Mn |
| Mar 31, 2026 | 4.02 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 3.91 Mn |
| Jun 30, 2025 | 3.91 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Mar 31, 2025 | 3.84 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Sep 30, 2024 | 3.73 Mn |
| Sep 30, 2024 | 3.73 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Jun 30, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Mar 31, 2024 | 3.72 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Dec 31, 2023 | 3.55 Mn |